Both in Pharmaceuticals
Atrium Therapeutics vs MacroGenics
Over the past year RNA returned −87.5% and MGNX returned +47.5%; their daily moves had a correlation of 0.00.
RNA −87.5% MGNX +47.5%Growth of $1, one year, split-adjusted
| Metric | RNA | MGNX |
|---|---|---|
| Price | $8.72 | $2.33 |
| Market cap | $149.2M | $148.4M |
| Today | +1.99% | 0.00% |
| 1 month | +9.4% | −38.2% |
| 6 months | −32.5% | −26.0% |
| Year to date | −87.9% | +44.7% |
| 1 year | — | +40.4% |
| Revenue growth (YoY) | −21.9% | +378.0% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −672.0% | 59.4% |
| P/E (TTM) | — | — |
| Price / sales | 4.1× | 0.9× |
| Net cash | $263.9M | $173.3M |
| Dividend yield | — | — |
| Volatility (60d) | 65.8% | 113.8% |
| Short % of float | 22.9% | 8.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).